Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Kottke

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Gene Therapy|December 18, 2009
Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanomaF Galivo, R M Diaz, P Wongthida, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|December 17, 2009
Lead identification and optimization of diaminopyrimidines as histamine H4 receptor ligandsK Sander, T Kottke, E Proschak, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|January 22, 2010
Search for novel, high affinity histamine H3 receptor ligands with fluorescent propertiesK J Kuder, T Kottke, H Stark, et al.
Gene Therapy|August 19, 2003
Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapyA Ahmed, D Jevremovic, K Suzuki, et al.
Gene Therapy|May 26, 2006
VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatmentJ Qiao, J Moreno, L Sanchez-Perez, et al.
Gene Therapy|April 21, 2006
The perforin-dependent immunological synapse allows T-cell activation-dependent tumor targeting by MLV vector particlesT Kottke, J Qiao, R M Diaz, et al.
Gene Therapy|April 20, 2007
Synergy of adoptive T-cell therapy and intratumoral suicide gene therapy is mediated by host NK cellsL Sanchez-Perez, M Gough, J Qiao, et al.
Preventive Medicine|September 26, 2001
A community-wide smoking cessation program: Quit and Win 1998 in Olmsted countyI T Croghan, M R O'Hara, D R Schroeder, et al.
Gene Therapy|March 14, 2009
Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunityE J Ilett, R J Prestwich, T Kottke, et al.
Gene Therapy|October 26, 2016
Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapyE Ilett, T Kottke, J Thompson, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Gene Therapy|December 18, 2009
Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanomaF Galivo, R M Diaz, P Wongthida, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|December 17, 2009
Lead identification and optimization of diaminopyrimidines as histamine H4 receptor ligandsK Sander, T Kottke, E Proschak, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|January 22, 2010
Search for novel, high affinity histamine H3 receptor ligands with fluorescent propertiesK J Kuder, T Kottke, H Stark, et al.
Gene Therapy|August 19, 2003
Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapyA Ahmed, D Jevremovic, K Suzuki, et al.
Gene Therapy|May 26, 2006
VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatmentJ Qiao, J Moreno, L Sanchez-Perez, et al.
Gene Therapy|April 21, 2006
The perforin-dependent immunological synapse allows T-cell activation-dependent tumor targeting by MLV vector particlesT Kottke, J Qiao, R M Diaz, et al.
Gene Therapy|April 20, 2007
Synergy of adoptive T-cell therapy and intratumoral suicide gene therapy is mediated by host NK cellsL Sanchez-Perez, M Gough, J Qiao, et al.
Preventive Medicine|September 26, 2001
A community-wide smoking cessation program: Quit and Win 1998 in Olmsted countyI T Croghan, M R O'Hara, D R Schroeder, et al.
Gene Therapy|March 14, 2009
Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunityE J Ilett, R J Prestwich, T Kottke, et al.
Gene Therapy|October 26, 2016
Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapyE Ilett, T Kottke, J Thompson, et al.
Pageof 3